Compare REED & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | REED | BEAT |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United States |
| Employees | 44 | 16 |
| Industry | | Retail: Computer Software & Peripheral Equipment |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.8M | 44.8M |
| IPO Year | N/A | N/A |
| Metric | REED | BEAT |
|---|---|---|
| Price | $3.58 | $0.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.63 |
| AVG Volume (30 Days) | 9.9K | ★ 1.4M |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.74 | N/A |
| Revenue Next Year | $18.00 | $315.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.75 | $0.54 |
| 52 Week High | $5.97 | $4.00 |
| Indicator | REED | BEAT |
|---|---|---|
| Relative Strength Index (RSI) | 46.96 | 35.88 |
| Support Level | $3.50 | $0.80 |
| Resistance Level | $4.35 | $1.29 |
| Average True Range (ATR) | 0.42 | 0.07 |
| MACD | -0.07 | 0.00 |
| Stochastic Oscillator | 41.67 | 29.97 |
Reed's Inc is a branded beverage company offering a portfolio of natural, premium, and functional beverages under the Reed's and Virgil's brands. The company's portfolio of handcrafted, all-natural beverages is sold in outlets nationwide, including the natural and specialty food channel, grocery stores, mass merchants, drug stores, convenience stores, club stores, and on-premise locations, including bars and restaurants. The company operates in a single reportable segment, which consists of manufacturing carbonated beverages under Reed's and Virgil's brand names.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.